Irocan 40, Irocan 100, Irocan 300, Irocan 500 40 mg, 100 mg, 300 mg or 500 mg Solution for Infusion
PDF Leaflet Revision Date: 20 October 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced colorectal cancer.
Dosage (summary)
350 mg/mu00b2 IV every 3 weeks for monotherapy; 80 mg/mu00b2 weekly or 180 mg/mu00b2 every 2 weeks for combination therapy.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; effective contraception required.
Key Drug Interactions
- Azole antifungals
- St John's Wort
- Live attenuated vaccines
Contraindications
- Severe hypersensitivity to irinotecan
- Chronic inflammatory bowel disease
- Bowel obstruction
- Bilirubin > 1.5 times ULN
- Severe bone marrow failure
- WHO performance status > 2
Common side effects
- Neutropenia
- Diarrhea
- Nausea
- Vomiting
- Alopecia
Counselling Points
- Avoid pregnancy during treatment
- Report diarrhea immediately
- Hydration is crucial
Serious warnings
- Risk of delayed diarrhea
- Severe neutropenia
- Monitor for infections
Important Disclaimer
The Irocan 40, Irocan 100, Irocan 300, Irocan 500 40 mg, 100 mg, 300 mg or 500 mg Solution for Infusion professional information leaflet below is the property of Innovata Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
